These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 28623376)
21. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739 [TBL] [Abstract][Full Text] [Related]
22. Feasibility of state of the art PET/CT systems performance harmonisation. Kaalep A; Sera T; Rijnsdorp S; Yaqub M; Talsma A; Lodge MA; Boellaard R Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1344-1361. PubMed ID: 29500480 [TBL] [Abstract][Full Text] [Related]
23. Predicting tumor response and outcome of second-look surgery with Aide N; Fauchille P; Coquan E; Ferron G; Combe P; Meunier J; Alexandre J; Berton D; Leary A; De Rauglaudre G; Bonichon N; Pujade Lauraine E; Joly F Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1998-2008. PubMed ID: 33221969 [TBL] [Abstract][Full Text] [Related]
24. EARL compliance and imaging optimisation on the Biograph Vision Quadra PET/CT using phantom and clinical data. van Sluis J; van Snick JH; Brouwers AH; Noordzij W; Dierckx RAJO; Borra RJH; Slart RHJA; Lammertsma AA; Glaudemans AWJM; Boellaard R; Tsoumpas C Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4652-4660. PubMed ID: 35876867 [TBL] [Abstract][Full Text] [Related]
25. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [ Lopci E; Hicks RJ; Dimitrakopoulou-Strauss A; Dercle L; Iravani A; Seban RD; Sachpekidis C; Humbert O; Gheysens O; Glaudemans AWJM; Weber W; Wahl RL; Scott AM; Pandit-Taskar N; Aide N Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2323-2341. PubMed ID: 35376991 [TBL] [Abstract][Full Text] [Related]
26. Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments. Pinker K; Riedl C; Weber WA Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):55-66. PubMed ID: 28361188 [TBL] [Abstract][Full Text] [Related]
27. Impact of PET reconstruction protocols on quantification of lesions that fulfil the PERCIST lesion inclusion criteria. Devriese J; Beels L; Maes A; Van de Wiele C; Pottel H EJNMMI Phys; 2018 Dec; 5(1):35. PubMed ID: 30523429 [TBL] [Abstract][Full Text] [Related]
28. Does PET Reconstruction Method Affect Deauville Score in Lymphoma Patients? Enilorac B; Lasnon C; Nganoa C; Fruchart C; Gac AC; Damaj G; Aide N J Nucl Med; 2018 Jul; 59(7):1049-1055. PubMed ID: 29242403 [TBL] [Abstract][Full Text] [Related]
29. Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients. Quak E; Le Roux PY; Hofman MS; Robin P; Bourhis D; Callahan J; Binns D; Desmonts C; Salaun PY; Hicks RJ; Aide N Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2072-82. PubMed ID: 26219870 [TBL] [Abstract][Full Text] [Related]
33. Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer. Woff E; Hendlisz A; Ameye L; Garcia C; Kamoun T; Guiot T; Paesmans M; Flamen P J Nucl Med; 2019 Feb; 60(2):178-184. PubMed ID: 29959212 [TBL] [Abstract][Full Text] [Related]
34. Standardization and quantification in FDG-PET/CT imaging for staging and restaging of malignant disease. Gámez-Cenzano C; Pino-Sorroche F PET Clin; 2014 Apr; 9(2):117-27. PubMed ID: 25030277 [TBL] [Abstract][Full Text] [Related]
35. Using PET for therapy monitoring in oncological clinical trials: challenges ahead. Deroose CM; Stroobants S; Liu Y; Shankar LK; Bourguet P Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):32-40. PubMed ID: 28451825 [TBL] [Abstract][Full Text] [Related]
36. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? Groheux D; Majdoub M; Tixier F; Le Rest CC; Martineau A; Merlet P; Espié M; de Roquancourt A; Hindié E; Hatt M; Visvikis D Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1682-1691. PubMed ID: 26140849 [TBL] [Abstract][Full Text] [Related]
37. Standardization of PET imaging and site qualification program by JSNM: collaboration with EANM/EARL. Senda M Ann Nucl Med; 2020 Nov; 34(11):873-874. PubMed ID: 32939687 [No Abstract] [Full Text] [Related]
38. Clinically feasible semi-automatic workflows for measuring metabolically active tumour volume in metastatic melanoma. van Sluis J; de Heer EC; Boellaard M; Jalving M; Brouwers AH; Boellaard R Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1498-1510. PubMed ID: 33099667 [TBL] [Abstract][Full Text] [Related]
39. Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology. Ziai P; Hayeri MR; Salei A; Salavati A; Houshmand S; Alavi A; Teytelboym OM Radiographics; 2016; 36(2):481-96. PubMed ID: 26963458 [TBL] [Abstract][Full Text] [Related]
40. New standards for phantom image quality and SUV harmonization range for multicenter oncology PET studies. Akamatsu G; Shimada N; Matsumoto K; Daisaki H; Suzuki K; Watabe H; Oda K; Senda M; Terauchi T; Tateishi U Ann Nucl Med; 2022 Feb; 36(2):144-161. PubMed ID: 35029817 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]